Fourpath Capital Management’s Medtronic MDT Stock Holding History

Fourpath Capital Management’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8M	Buy	92,355 +4,643	+5%	+$445K	1.15%	20
2025 Q4	$8.43M	Buy	87,712 +69	+0.1%	+$6.7K	1.15%	24
2025 Q3	$8.35M	Buy	87,643 +73	+0.1%	+$6.71K	1.19%	25
2025 Q2	$7.63M	Buy	87,570 +75	+0.1%	+$6.36K	1.2%	19
2025 Q1	$7.86M	Buy	87,495 +80	+0.1%	+$7.16K	1.37%	19
2024 Q4	$6.98M	Sell	87,415 -46	-0.1%	-$3.98K	1.29%	19
2024 Q3	$7.87M	Buy	+87,461	New	+$7.36M	1.45%	15
2024 Q1	–	Sell	-6,852	Closed	-$565K	–	145
2023 Q4	$565K	Sell	6,852 -276	-4%	-$21K	0.38%	56
2023 Q3	$559K	Buy	7,128 +786	+12%	+$65.8K	0.42%	60
2023 Q2	$559K	Sell	6,342 -81	-1%	-$6.97K	0.67%	46
2023 Q1	$518K	Sell	6,423 -12	-0.2%	-$978	0.36%	70
2022 Q4	$500K	Buy	+6,435	New	+$522K	0.36%	72
2022 Q1	–	Sell	-2,659	Closed	-$275K	–	169
2021 Q4	$275K	Buy	+2,659	New	+$308K	0.11%	129

Other funds holding MDT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fourpath Capital Management's MDT Position: Q1 2026 in Review

Fourpath Capital Management increased its Medtronic (MDT) stake by 5.3% in Q1 2026, buying an estimated $445K and bringing the position to 92,355 shares worth $8M. The position accounts for 1.15% of the portfolio, ranked #20.

Fourpath Capital Management first reported a position in MDT in Q4 2021 and has held it in 13 quarters since. The position peaked at $8.43M in Q4 2025. 2,229 funds tracked by Wall St. Rank hold MDT as of Q1 2026.

Fourpath Capital Management held 92,355 shares of Medtronic worth $8M as of Q1 2026.
Fourpath Capital Management bought 4,643 Medtronic shares in Q1 2026, an estimated $445K.
Medtronic made up 1.15% of Fourpath Capital Management's portfolio in Q1 2026, its #20 holding.
Fourpath Capital Management first reported a position in Medtronic in Q4 2021 and has held it in 13 quarters since.
Fourpath Capital Management's Medtronic position peaked at $8.43M in Q4 2025.
2,229 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.

Based on Fourpath Capital Management's 13F filing for Q1 2026, filed 1 May 2026.